Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Free Report) – Stock analysts at Edison Inv. Res issued their FY2025 earnings per share estimates for shares of Basilea Pharmaceutica in a research note issued to investors on Thursday, March 27th. Edison Inv. Res analyst J. Prakash forecasts that the company will post earnings of $4.76 per share for the year.
Basilea Pharmaceutica Stock Performance
BPMUF opened at $54.00 on Monday. Basilea Pharmaceutica has a 12-month low of $38.60 and a 12-month high of $54.00. The company has a current ratio of 4.10, a quick ratio of 3.27 and a debt-to-equity ratio of 5.70. The stock has a fifty day simple moving average of $52.95 and a two-hundred day simple moving average of $52.64.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
See Also
- Five stocks we like better than Basilea Pharmaceutica
- How to Use the MarketBeat Stock Screener
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- How to Most Effectively Use the MarketBeat Earnings Screener
- MarketBeat Week in Review – 03/24 – 03/28
- What is the Dogs of the Dow Strategy? Overview and Examples
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
